Bridging Medical Specialities in the Management of Polycystic Ovary Syndrome: Integrating Lessons from Sodium-glucose Cotransporter-2 Inhibitors into a Holistic Approach
Abstract
Polycystic ovary syndrome presents significant metabolic, dermatologic and gynaecologic challenges, including hyperandrogenism, menstrual irregularities and obesity. While patients often consult different specialists for dermatologic or gynaecologic concerns, effective management requires placing metabolic health at the centre of all specialities involved; from endocrinology to nutrition. Traditional boundaries between specialities are fading, creating a more unified approach focused on metabolic management. This centralization fosters comprehensive strategies to address both immediate symptoms and long-term risks, leading to improved, holistic patient outcomes.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.